{"transactions":[{"id":679726,"issuer":{"id":5986,"kind":"organization","name":"Pyxis Oncology, Inc.","symbol":"PYXS"},"owners":[{"id":21169,"kind":"person","name":"Dupont Jakob","position":1,"cik":"0001553335","reported_name":"Dupont Jakob","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2026-08-20T22:18:31.000Z","date":"2026-08-20","kind":"grant","planned":false,"acquired":true,"shares":46000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares subject to this option will vest in equal monthly installments through October 31, 2026, subject to the reporting person's continued service through the applicable vesting date."}],"balance_after":46000,"derivative":{"exercise_price":3.12,"expiration_date":"2036-08-20","underlying":"Common Stock","underlying_shares":46000},"source":{"system":"sec-edgar","filing":"0001193125-26-359525","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1553335/000119312526359525/ownership.xml","form_type":"4"}},{"id":717282,"issuer":{"id":5986,"kind":"organization","name":"Pyxis Oncology, Inc.","symbol":"PYXS"},"owners":[{"id":21169,"kind":"person","name":"Dupont Jakob","position":1,"cik":"0001553335","reported_name":"Dupont Jakob","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2026-07-02T20:30:46.000Z","date":"2026-06-30","kind":"exercise","planned":true,"acquired":false,"shares":35000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"Award of stock options to purchase Common Shares with a vesting commencement date of August 23, 2024. These options vest and become exercisable in three equal annual tranches from August 23, 2023, subject generally to the reporting person's continuous service through each vesting date (unless otherwise provided in the applicable award documentation)."}],"balance_after":357461,"derivative":{"exercise_price":1.6,"expiration_date":"2033-09-22","underlying":"Common Stock","underlying_shares":35000},"source":{"system":"sec-edgar","filing":"0001193125-26-294708","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1553335/000119312526294708/ownership.xml","form_type":"4"}},{"id":717281,"issuer":{"id":5986,"kind":"organization","name":"Pyxis Oncology, Inc.","symbol":"PYXS"},"owners":[{"id":21169,"kind":"person","name":"Dupont Jakob","position":1,"cik":"0001553335","reported_name":"Dupont Jakob","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-07-02T20:30:46.000Z","date":"2026-06-30","kind":"sale","planned":true,"acquired":false,"shares":35000,"price":3.06,"value":107100.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on Septemeber 24, 2025."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Reflects sales of common stock executed in multiple transactions. The price reported reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request by the Securities and Exchange Commission staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the sales were effected within the ranges set forth in footnotes 3 of this Form 4."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The transaction was executed in multiple trades in prices ranging from $3.00 to $3.36."}],"balance_after":38741,"source":{"system":"sec-edgar","filing":"0001193125-26-294708","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1553335/000119312526294708/ownership.xml","form_type":"4"}},{"id":717280,"issuer":{"id":5986,"kind":"organization","name":"Pyxis Oncology, Inc.","symbol":"PYXS"},"owners":[{"id":21169,"kind":"person","name":"Dupont Jakob","position":1,"cik":"0001553335","reported_name":"Dupont Jakob","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-07-02T20:30:46.000Z","date":"2026-06-30","kind":"exercise","planned":true,"acquired":true,"shares":35000,"price":1.6,"value":56000.0,"ownership":{"direct":true},"balance_after":73741,"source":{"system":"sec-edgar","filing":"0001193125-26-294708","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1553335/000119312526294708/ownership.xml","form_type":"4"}},{"id":741683,"issuer":{"id":8082,"kind":"organization","name":"Bolt Biotherapeutics, Inc.","symbol":"BOLT"},"owners":[{"id":21169,"kind":"person","name":"Dupont Jakob","position":1,"cik":"0001553335","reported_name":"Dupont Jakob","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2026-06-11T20:12:02.000Z","date":"2026-06-10","kind":"grant","planned":false,"acquired":true,"shares":5000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares subject to the option will vest on the earlier of June 9, 2027 or the day immediately prior to the next annual meeting of stockholders, subject to the Reporting Person's continuous service through such date; provided, however that the option will vest in full upon a change in control of the Issuer."}],"balance_after":5000,"derivative":{"exercise_price":4.43,"expiration_date":"2036-06-09","underlying":"Common Stock","underlying_shares":5000},"source":{"system":"sec-edgar","filing":"0001193125-26-267546","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1641281/000119312526267546/ownership.xml","form_type":"4"}},{"id":828079,"issuer":{"id":5986,"kind":"organization","name":"Pyxis Oncology, Inc.","symbol":"PYXS"},"owners":[{"id":21169,"kind":"person","name":"Dupont Jakob","position":1,"cik":"0001553335","reported_name":"Dupont Jakob","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2026-03-25T21:18:44.000Z","date":"2026-03-24","kind":"grant","planned":false,"acquired":true,"shares":45867,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares subject to this option will vest 100% on the first anniversary of the grant date, subject to the reporting person's continued service through the applicable vesting date."}],"balance_after":45867,"derivative":{"exercise_price":1.36,"expiration_date":"2036-03-24","underlying":"Common Stock","underlying_shares":45867},"source":{"system":"sec-edgar","filing":"0001193125-26-124388","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1553335/000119312526124388/ownership.xml","form_type":"4"}},{"id":967543,"issuer":{"id":8082,"kind":"organization","name":"Bolt Biotherapeutics, Inc.","symbol":"BOLT"},"owners":[{"id":21169,"kind":"person","name":"Dupont Jakob","position":1,"cik":"0001553335","reported_name":"Dupont Jakob","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Director Stock Option (Right to Buy)","published_at":"2025-12-16T22:15:09.000Z","date":"2025-12-12","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":1100,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F7","text":"The reporting person agreed to cancellation of an option granted on May 27, 2025, in exchange for a new option having a lower exercise price."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F6","text":"The shares subject to the option will vest on the earlier of May 27, 2026 or the day immediately prior to the next annual meeting of stockholders, subject to the Reporting Person's continuous service through such date; provided, however that the option will vest in full upon a change in control of the Issuer."}],"balance_after":0,"derivative":{"exercise_price":6.4,"expiration_date":"2035-05-26","underlying":"Common Stock","underlying_shares":1100},"source":{"system":"sec-edgar","filing":"0001193125-25-321156","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":8,"url":"https://www.sec.gov/Archives/edgar/data/1641281/000119312525321156/ownership.xml","form_type":"4"}},{"id":967542,"issuer":{"id":8082,"kind":"organization","name":"Bolt Biotherapeutics, Inc.","symbol":"BOLT"},"owners":[{"id":21169,"kind":"person","name":"Dupont Jakob","position":1,"cik":"0001553335","reported_name":"Dupont Jakob","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Director Stock Option (Right to Buy)","published_at":"2025-12-16T22:15:09.000Z","date":"2025-12-12","kind":"grant","planned":false,"acquired":true,"shares":1100,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F7","text":"The reporting person agreed to cancellation of an option granted on May 27, 2025, in exchange for a new option having a lower exercise price."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F6","text":"The shares subject to the option will vest on the earlier of May 27, 2026 or the day immediately prior to the next annual meeting of stockholders, subject to the Reporting Person's continuous service through such date; provided, however that the option will vest in full upon a change in control of the Issuer."}],"balance_after":1100,"derivative":{"exercise_price":5.44,"expiration_date":"2035-05-26","underlying":"Common Stock","underlying_shares":1100},"source":{"system":"sec-edgar","filing":"0001193125-25-321156","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/1641281/000119312525321156/ownership.xml","form_type":"4"}},{"id":967541,"issuer":{"id":8082,"kind":"organization","name":"Bolt Biotherapeutics, Inc.","symbol":"BOLT"},"owners":[{"id":21169,"kind":"person","name":"Dupont Jakob","position":1,"cik":"0001553335","reported_name":"Dupont Jakob","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Director Stock Option (Right to Buy)","published_at":"2025-12-16T22:15:09.000Z","date":"2025-12-12","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":1000,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F5","text":"The reporting person agreed to cancellation of an option granted on May 1, 2025, in exchange for a new option having a lower exercise price."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The option is fully vested and exercisable."}],"balance_after":0,"derivative":{"exercise_price":7.02,"expiration_date":"2035-04-30","underlying":"Common Stock","underlying_shares":1000},"source":{"system":"sec-edgar","filing":"0001193125-25-321156","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1641281/000119312525321156/ownership.xml","form_type":"4"}},{"id":967540,"issuer":{"id":8082,"kind":"organization","name":"Bolt Biotherapeutics, Inc.","symbol":"BOLT"},"owners":[{"id":21169,"kind":"person","name":"Dupont Jakob","position":1,"cik":"0001553335","reported_name":"Dupont Jakob","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Director Stock Option (Right to Buy)","published_at":"2025-12-16T22:15:09.000Z","date":"2025-12-12","kind":"grant","planned":false,"acquired":true,"shares":1000,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F5","text":"The reporting person agreed to cancellation of an option granted on May 1, 2025, in exchange for a new option having a lower exercise price."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The option is fully vested and exercisable."}],"balance_after":1000,"derivative":{"exercise_price":5.44,"expiration_date":"2035-04-30","underlying":"Common Stock","underlying_shares":1000},"source":{"system":"sec-edgar","filing":"0001193125-25-321156","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1641281/000119312525321156/ownership.xml","form_type":"4"}},{"id":967539,"issuer":{"id":8082,"kind":"organization","name":"Bolt Biotherapeutics, Inc.","symbol":"BOLT"},"owners":[{"id":21169,"kind":"person","name":"Dupont Jakob","position":1,"cik":"0001553335","reported_name":"Dupont Jakob","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Director Stock Option (Right to Buy)","published_at":"2025-12-16T22:15:09.000Z","date":"2025-12-12","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":849,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F4","text":"The reporting person agreed to cancellation of an option granted on September 3, 2024, in exchange for a new option having a lower exercise price."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The option is fully vested and exercisable."}],"balance_after":0,"derivative":{"exercise_price":13.596,"expiration_date":"2034-09-02","underlying":"Common Stock","underlying_shares":849},"source":{"system":"sec-edgar","filing":"0001193125-25-321156","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1641281/000119312525321156/ownership.xml","form_type":"4"}},{"id":967538,"issuer":{"id":8082,"kind":"organization","name":"Bolt Biotherapeutics, Inc.","symbol":"BOLT"},"owners":[{"id":21169,"kind":"person","name":"Dupont Jakob","position":1,"cik":"0001553335","reported_name":"Dupont Jakob","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Director Stock Option (Right to Buy)","published_at":"2025-12-16T22:15:09.000Z","date":"2025-12-12","kind":"grant","planned":false,"acquired":true,"shares":849,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F4","text":"The reporting person agreed to cancellation of an option granted on September 3, 2024, in exchange for a new option having a lower exercise price."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The option is fully vested and exercisable."}],"balance_after":849,"derivative":{"exercise_price":5.44,"expiration_date":"2034-09-02","underlying":"Common Stock","underlying_shares":849},"source":{"system":"sec-edgar","filing":"0001193125-25-321156","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1641281/000119312525321156/ownership.xml","form_type":"4"}},{"id":967537,"issuer":{"id":8082,"kind":"organization","name":"Bolt Biotherapeutics, Inc.","symbol":"BOLT"},"owners":[{"id":21169,"kind":"person","name":"Dupont Jakob","position":1,"cik":"0001553335","reported_name":"Dupont Jakob","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Director Stock Option (Right to Buy)","published_at":"2025-12-16T22:15:09.000Z","date":"2025-12-12","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":2500,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The reporting person agreed to cancellation of an option granted on September 3, 2024, in exchange for a new option having a lower exercise price."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"For so long as the Reporting Person continuously provides services to the Issuer this option will vest with respect to the shares as follows: 1/36th of the shares will vest upon the Reporting Person completing each month of continuous service following September 3, 2024; provided, however that the option will vest in full upon a change in control."}],"balance_after":0,"derivative":{"exercise_price":13.596,"expiration_date":"2034-09-02","underlying":"Common Stock","underlying_shares":2500},"source":{"system":"sec-edgar","filing":"0001193125-25-321156","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1641281/000119312525321156/ownership.xml","form_type":"4"}},{"id":967536,"issuer":{"id":8082,"kind":"organization","name":"Bolt Biotherapeutics, Inc.","symbol":"BOLT"},"owners":[{"id":21169,"kind":"person","name":"Dupont Jakob","position":1,"cik":"0001553335","reported_name":"Dupont Jakob","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Director Stock Option (Right to Buy)","published_at":"2025-12-16T22:15:09.000Z","date":"2025-12-12","kind":"grant","planned":false,"acquired":true,"shares":2500,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The reporting person agreed to cancellation of an option granted on September 3, 2024, in exchange for a new option having a lower exercise price."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"For so long as the Reporting Person continuously provides services to the Issuer this option will vest with respect to the shares as follows: 1/36th of the shares will vest upon the Reporting Person completing each month of continuous service following September 3, 2024; provided, however that the option will vest in full upon a change in control."}],"balance_after":2500,"derivative":{"exercise_price":5.44,"expiration_date":"2034-09-02","underlying":"Common Stock","underlying_shares":2500},"source":{"system":"sec-edgar","filing":"0001193125-25-321156","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1641281/000119312525321156/ownership.xml","form_type":"4"}},{"id":1095135,"issuer":{"id":8082,"kind":"organization","name":"Bolt Biotherapeutics, Inc.","symbol":"BOLT"},"owners":[{"id":21169,"kind":"person","name":"Dupont Jakob","position":1,"cik":"0001553335","reported_name":"Dupont Jakob","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2025-07-02T20:05:38.000Z","date":"2025-05-27","kind":"grant","planned":false,"acquired":true,"shares":1100,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"On June 6, 2025, the Company effected a 1-for-20 reverse stock split of its common stock. All share and exercise price amounts reported herein reflect the reverse stock split. Prior to the reverse stock split, the reporting person was granted options to purchase 22,000 shares at an exercise price of $0.3200 per share."},{"field":"shares","element":"transactionShares","label":"F1","text":"On June 6, 2025, the Company effected a 1-for-20 reverse stock split of its common stock. All share and exercise price amounts reported herein reflect the reverse stock split. Prior to the reverse stock split, the reporting person was granted options to purchase 22,000 shares at an exercise price of $0.3200 per share."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The shares subject to the option will vest on the earlier of May 27, 2026 or the day immediately prior to the next annual meeting of stockholders, subject to the Reporting Person's continuous service through such date; provided, however that the option will vest in full upon a change in control of the Issuer."},{"field":"derivative.underlying_shares","element":"underlyingSecurityShares","label":"F1","text":"On June 6, 2025, the Company effected a 1-for-20 reverse stock split of its common stock. All share and exercise price amounts reported herein reflect the reverse stock split. Prior to the reverse stock split, the reporting person was granted options to purchase 22,000 shares at an exercise price of $0.3200 per share."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F1","text":"On June 6, 2025, the Company effected a 1-for-20 reverse stock split of its common stock. All share and exercise price amounts reported herein reflect the reverse stock split. Prior to the reverse stock split, the reporting person was granted options to purchase 22,000 shares at an exercise price of $0.3200 per share."}],"balance_after":1100,"derivative":{"exercise_price":6.4,"expiration_date":"2035-05-26","underlying":"Common Stock","underlying_shares":1100},"source":{"system":"sec-edgar","filing":"0000950170-25-092941","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1641281/000095017025092941/ownership.xml","form_type":"4"}},{"id":1159192,"issuer":{"id":8082,"kind":"organization","name":"Bolt Biotherapeutics, Inc.","symbol":"BOLT"},"owners":[{"id":21169,"kind":"person","name":"Dupont Jakob","position":1,"cik":"0001553335","reported_name":"Dupont Jakob","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2025-05-06T01:28:46.000Z","date":"2025-05-01","kind":"grant","planned":false,"acquired":true,"shares":20000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"For so long as the Reporting Person continuously provides services to the Issuer this option will vest with respect to the shares as follows: 1/6th of the Shares will vest upon the Reporting Person completing each month of continuous service following May 1, 2025."}],"balance_after":20000,"derivative":{"exercise_price":0.351,"expiration_date":"2035-04-30","underlying":"Common Stock","underlying_shares":20000},"source":{"system":"sec-edgar","filing":"0000950170-25-063886","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1641281/000095017025063886/ownership.xml","form_type":"4"}},{"id":1182682,"issuer":{"id":5986,"kind":"organization","name":"Pyxis Oncology, Inc.","symbol":"PYXS"},"owners":[{"id":21169,"kind":"person","name":"Dupont Jakob","position":1,"cik":"0001553335","reported_name":"Dupont Jakob","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2025-04-02T13:00:15.000Z","date":"2025-03-31","kind":"grant","planned":false,"acquired":true,"shares":36979,"price":0.98,"value":36239.42,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares subject to this option will vest 100% on the first anniversary of the grant date, subject to the reporting person's continued service through the applicable vesting date."}],"balance_after":36979,"derivative":{"exercise_price":0.98,"expiration_date":"2035-03-31","underlying":"Common Stock","underlying_shares":36979},"source":{"system":"sec-edgar","filing":"0000950170-25-048898","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1553335/000095017025048898/ownership.xml","form_type":"4"}},{"id":1412726,"issuer":{"id":8082,"kind":"organization","name":"Bolt Biotherapeutics, Inc.","symbol":"BOLT"},"owners":[{"id":21169,"kind":"person","name":"Dupont Jakob","position":1,"cik":"0001553335","reported_name":"Dupont Jakob","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2024-09-06T16:19:51.000Z","date":"2024-09-03","kind":"grant","planned":false,"acquired":true,"shares":16984,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The shares subject to this option shall vest in full on the date immediately preceding the date of the Issuer's next annual stockholder meeting for so long as the Reporting Person is serving as a director of the Issuer on such date; provided, however that the option will vest in full upon a change in control."}],"balance_after":16984,"derivative":{"exercise_price":0.6798,"expiration_date":"2034-09-02","underlying":"Common Stock","underlying_shares":16984},"source":{"system":"sec-edgar","filing":"0001415889-24-023005","document":"form4-09062024_040947.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1641281/000141588924023005/form4-09062024_040947.xml","form_type":"4"}},{"id":1412725,"issuer":{"id":8082,"kind":"organization","name":"Bolt Biotherapeutics, Inc.","symbol":"BOLT"},"owners":[{"id":21169,"kind":"person","name":"Dupont Jakob","position":1,"cik":"0001553335","reported_name":"Dupont Jakob","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2024-09-06T16:19:51.000Z","date":"2024-09-03","kind":"grant","planned":false,"acquired":true,"shares":50000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"For so long as the Reporting Person continuously provides services to the Issuer this option will vest with respect to the shares as follows: 1/36th of the shares will vest upon the Reporting Person completing each month of continuous service following September 3, 2024; provided, however that the option will vest in full upon a change in control."}],"balance_after":50000,"derivative":{"exercise_price":0.6798,"expiration_date":"2034-09-02","underlying":"Common Stock","underlying_shares":50000},"source":{"system":"sec-edgar","filing":"0001415889-24-023005","document":"form4-09062024_040947.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1641281/000141588924023005/form4-09062024_040947.xml","form_type":"4"}},{"id":1558215,"issuer":{"id":5986,"kind":"organization","name":"Pyxis Oncology, Inc.","symbol":"PYXS"},"owners":[{"id":21169,"kind":"person","name":"Dupont Jakob","position":1,"cik":"0001553335","reported_name":"Dupont Jakob","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2024-03-28T20:32:39.000Z","date":"2024-03-26","kind":"grant","planned":false,"acquired":true,"shares":38741,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents restricted stock units that vest 100% on the first anniversary of the grant date, subject to the reporting person's continued service through the applicable vesting date."}],"balance_after":38741,"source":{"system":"sec-edgar","filing":"0000950170-24-038102","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1553335/000095017024038102/ownership.xml","form_type":"4"}},{"id":1773089,"issuer":{"id":5986,"kind":"organization","name":"Pyxis Oncology, Inc.","symbol":"PYXS"},"owners":[{"id":21169,"kind":"person","name":"Dupont Jakob","position":1,"cik":"0001553335","reported_name":"Dupont Jakob","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2023-09-26T23:04:57.000Z","date":"2023-09-22","kind":"grant","planned":false,"acquired":true,"shares":392461,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"These stock options vest in three equal annual installments beginning on the first anniversary of August 23, 2023, subject to the reporting person's continued service through the applicable vesting date."}],"balance_after":392461,"derivative":{"exercise_price":1.6,"expiration_date":"2033-09-22","underlying":"Common Stock","underlying_shares":392461},"source":{"system":"sec-edgar","filing":"0001209191-23-050613","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1553335/000120919123050613/doc4.xml","form_type":"4"}},{"id":1796041,"issuer":{"id":5986,"kind":"organization","name":"Pyxis Oncology, Inc.","symbol":"PYXS"},"owners":[{"id":21169,"kind":"person","name":"Dupont Jakob","position":1,"cik":"0001553335","reported_name":"Dupont Jakob","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to buy)","published_at":"2023-08-25T21:30:50.000Z","date":"2023-08-23","kind":"grant","planned":false,"acquired":true,"shares":17250,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"On May 23, 2023, the Issuer, Ascent Merger Sub Corp., a wholly-owned subsidiary of the Issuer, or the Merger Sub, and Apexigen, Inc., or Apexigen, entered into a definitive agreement for the Issuer to acquire Apexigen, or the Merger Agreement. Under the terms of the Merger Agreement, the reporting person's options to purchase shares of Apexigen Common Stock, or the Apexigen Options, that were outstanding immediately prior to the effective time of the merger were assumed by the Issuer and converted into options to acquire, on substantially similar terms and conditions, the number of shares of the Issuer Common Stock determined by multiplying the number of shares subject to the Apexigen Options by 0.1725, or the Exchange Ratio, shares of the Issuer Common Stock, rounded down to the nearest whole share, with an exercise price per share equal to the exercise price per share of such Apexigen Option divided by the Exchange Ratio, rounded up to the nearest whole cent."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares subject to this option vested in full immediately prior to the closing of the merger described in footnote 2."}],"balance_after":17250,"derivative":{"exercise_price":15.37,"expiration_date":"2032-09-29","underlying":"Common Stock","underlying_shares":17250},"source":{"system":"sec-edgar","filing":"0001209191-23-047384","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1553335/000120919123047384/doc4.xml","form_type":"4"}},{"id":1796040,"issuer":{"id":5986,"kind":"organization","name":"Pyxis Oncology, Inc.","symbol":"PYXS"},"owners":[{"id":21169,"kind":"person","name":"Dupont Jakob","position":1,"cik":"0001553335","reported_name":"Dupont Jakob","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to buy)","published_at":"2023-08-25T21:30:50.000Z","date":"2023-08-23","kind":"grant","planned":false,"acquired":true,"shares":3534,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"On May 23, 2023, the Issuer, Ascent Merger Sub Corp., a wholly-owned subsidiary of the Issuer, or the Merger Sub, and Apexigen, Inc., or Apexigen, entered into a definitive agreement for the Issuer to acquire Apexigen, or the Merger Agreement. Under the terms of the Merger Agreement, the reporting person's options to purchase shares of Apexigen Common Stock, or the Apexigen Options, that were outstanding immediately prior to the effective time of the merger were assumed by the Issuer and converted into options to acquire, on substantially similar terms and conditions, the number of shares of the Issuer Common Stock determined by multiplying the number of shares subject to the Apexigen Options by 0.1725, or the Exchange Ratio, shares of the Issuer Common Stock, rounded down to the nearest whole share, with an exercise price per share equal to the exercise price per share of such Apexigen Option divided by the Exchange Ratio, rounded up to the nearest whole cent."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares subject to this option vested in full immediately prior to the closing of the merger described in footnote 2."}],"balance_after":3534,"derivative":{"exercise_price":26.61,"expiration_date":"2031-02-12","underlying":"Common Stock","underlying_shares":3534},"source":{"system":"sec-edgar","filing":"0001209191-23-047384","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1553335/000120919123047384/doc4.xml","form_type":"4"}},{"id":1796039,"issuer":{"id":5986,"kind":"organization","name":"Pyxis Oncology, Inc.","symbol":"PYXS"},"owners":[{"id":21169,"kind":"person","name":"Dupont Jakob","position":1,"cik":"0001553335","reported_name":"Dupont Jakob","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to buy)","published_at":"2023-08-25T21:30:50.000Z","date":"2023-08-23","kind":"grant","planned":false,"acquired":true,"shares":5879,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"On May 23, 2023, the Issuer, Ascent Merger Sub Corp., a wholly-owned subsidiary of the Issuer, or the Merger Sub, and Apexigen, Inc., or Apexigen, entered into a definitive agreement for the Issuer to acquire Apexigen, or the Merger Agreement. Under the terms of the Merger Agreement, the reporting person's options to purchase shares of Apexigen Common Stock, or the Apexigen Options, that were outstanding immediately prior to the effective time of the merger were assumed by the Issuer and converted into options to acquire, on substantially similar terms and conditions, the number of shares of the Issuer Common Stock determined by multiplying the number of shares subject to the Apexigen Options by 0.1725, or the Exchange Ratio, shares of the Issuer Common Stock, rounded down to the nearest whole share, with an exercise price per share equal to the exercise price per share of such Apexigen Option divided by the Exchange Ratio, rounded up to the nearest whole cent."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares subject to this option vested in full immediately prior to the closing of the merger described in footnote 2."}],"balance_after":5879,"derivative":{"exercise_price":26.61,"expiration_date":"2030-09-01","underlying":"Common Stock","underlying_shares":5879},"source":{"system":"sec-edgar","filing":"0001209191-23-047384","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1553335/000120919123047384/doc4.xml","form_type":"4"}},{"id":1796469,"issuer":{"id":110214,"kind":"organization","name":"Apexigen, Inc.","symbol":"APGN"},"owners":[{"id":21169,"kind":"person","name":"Dupont Jakob","position":1,"cik":"0001553335","reported_name":"Dupont Jakob","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2023-08-25T19:29:10.000Z","date":"2023-08-23","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":100000,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F4","text":"The shares subject to the option vest in three equal annual installments beginning on July 29, 2023. Pursuant to the Merger Agreement, at the Effective Time, the option was assumed by Pyxis and converted into an option to purchase 17,250 shares of Pyxis common stock at an exercise price of $15.37 per share. In accordance with the reporting person's equity award agreement, vesting of the unvested shares underlying the option accelerated in full at the Effective Time."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"The shares subject to the option vest in three equal annual installments beginning on July 29, 2023. Pursuant to the Merger Agreement, at the Effective Time, the option was assumed by Pyxis and converted into an option to purchase 17,250 shares of Pyxis common stock at an exercise price of $15.37 per share. In accordance with the reporting person's equity award agreement, vesting of the unvested shares underlying the option accelerated in full at the Effective Time."}],"balance_after":0,"derivative":{"exercise_price":2.65,"expiration_date":"2032-09-29","underlying":"Common Stock","underlying_shares":100000},"source":{"system":"sec-edgar","filing":"0001209191-23-047446","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1814140/000120919123047446/doc4.xml","form_type":"4"}},{"id":1796468,"issuer":{"id":110214,"kind":"organization","name":"Apexigen, Inc.","symbol":"APGN"},"owners":[{"id":21169,"kind":"person","name":"Dupont Jakob","position":1,"cik":"0001553335","reported_name":"Dupont Jakob","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2023-08-25T19:29:10.000Z","date":"2023-08-23","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":20489,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F2","text":"This exercise price was reported incorrectly as $4.49 in a Form 3/A filed on August 24, 2023."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The shares subject to the option vest upon the achievement of certain performance metrics. Pursuant to the Merger Agreement, at the Effective Time, the option was assumed by Pyxis and converted into an option to purchase 3,534 shares of Pyxis common stock at an exercise price of $26.61 per share. In accordance with the reporting person's equity award agreement, vesting of the unvested shares underlying the option accelerated in full at the Effective Time."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The shares subject to the option vest upon the achievement of certain performance metrics. Pursuant to the Merger Agreement, at the Effective Time, the option was assumed by Pyxis and converted into an option to purchase 3,534 shares of Pyxis common stock at an exercise price of $26.61 per share. In accordance with the reporting person's equity award agreement, vesting of the unvested shares underlying the option accelerated in full at the Effective Time."}],"balance_after":0,"derivative":{"exercise_price":4.59,"expiration_date":"2031-02-12","underlying":"Common Stock","underlying_shares":20489},"source":{"system":"sec-edgar","filing":"0001209191-23-047446","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1814140/000120919123047446/doc4.xml","form_type":"4"}},{"id":1796467,"issuer":{"id":110214,"kind":"organization","name":"Apexigen, Inc.","symbol":"APGN"},"owners":[{"id":21169,"kind":"person","name":"Dupont Jakob","position":1,"cik":"0001553335","reported_name":"Dupont Jakob","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2023-08-25T19:29:10.000Z","date":"2023-08-23","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":34084,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The shares subject to the option vest in 48 equal monthly installments beginning on September 10, 2020. Pursuant to an Agreement and Plan of Merger, dated as of May 23, 2023 (the \"Merger Agreement\"), by and among the Issuer, Pyxis Oncology, Inc. (\"Pyxis\"), and Ascent Merger Sub Corp., at the effective time of the merger (the \"Effective Time\"), the option was assumed by Pyxis and converted into an option to purchase 5,879 shares of Pyxis common stock at an exercise price of $26.61 per share. In accordance with the reporting person's equity award agreement, vesting of the unvested shares underlying the option accelerated in full at the Effective Time."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares subject to the option vest in 48 equal monthly installments beginning on September 10, 2020. Pursuant to an Agreement and Plan of Merger, dated as of May 23, 2023 (the \"Merger Agreement\"), by and among the Issuer, Pyxis Oncology, Inc. (\"Pyxis\"), and Ascent Merger Sub Corp., at the effective time of the merger (the \"Effective Time\"), the option was assumed by Pyxis and converted into an option to purchase 5,879 shares of Pyxis common stock at an exercise price of $26.61 per share. In accordance with the reporting person's equity award agreement, vesting of the unvested shares underlying the option accelerated in full at the Effective Time."}],"balance_after":0,"derivative":{"exercise_price":4.59,"expiration_date":"2030-09-01","underlying":"Common Stock","underlying_shares":34084},"source":{"system":"sec-edgar","filing":"0001209191-23-047446","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1814140/000120919123047446/doc4.xml","form_type":"4"}},{"id":1968345,"issuer":{"id":6828,"kind":"organization","name":"Atara Biotherapeutics, Inc.","symbol":"ATRA"},"owners":[{"id":21169,"kind":"person","name":"Dupont Jakob","position":1,"cik":"0001553335","reported_name":"Dupont Jakob","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Head of R&D"}}],"security":"Common Stock","published_at":"2023-03-06T23:46:39.000Z","date":"2023-03-02","kind":"sale","acquired":false,"shares":5074,"price":3.627,"value":18403.398,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Shares sold pursuant to a 10b5-1 arrangement to satisfy tax obligations in connection with the vesting of previously granted restricted stock units."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The sale price of the reporting person's shares represents the weighted average price of all shares sold by a broker on March 2, 2023 and March 3, 2023 on behalf of a group of employees of the Issuer to satisfy the payment of withholding tax liability of such employee."}],"balance_after":290794,"source":{"system":"sec-edgar","filing":"0001567619-23-004537","document":"doc1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1553335/000156761923004537/doc1.xml","form_type":"4"}},{"id":1971850,"issuer":{"id":6828,"kind":"organization","name":"Atara Biotherapeutics, Inc.","symbol":"ATRA"},"owners":[{"id":21169,"kind":"person","name":"Dupont Jakob","position":1,"cik":"0001553335","reported_name":"Dupont Jakob","relationship":{"officer":true,"officer_title":"EVP, Head of R&D"}}],"security":"Employee Stock Option (Right to Buy)","published_at":"2023-03-03T22:15:58.000Z","date":"2023-03-01","kind":"grant","acquired":true,"shares":317987,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"1/36th of the shares subject to the stock option vest and become exercisable each month, with the initial installment vesting on April 1, 2023, subject to the reporting person's continuous service."}],"balance_after":317987,"derivative":{"exercise_price":3.91,"expiration_date":"2033-02-28","underlying":"Common Stock","underlying_shares":317987},"source":{"system":"sec-edgar","filing":"0001140361-23-010100","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1553335/000114036123010100/form4.xml","form_type":"4"}},{"id":1971849,"issuer":{"id":6828,"kind":"organization","name":"Atara Biotherapeutics, Inc.","symbol":"ATRA"},"owners":[{"id":21169,"kind":"person","name":"Dupont Jakob","position":1,"cik":"0001553335","reported_name":"Dupont Jakob","relationship":{"officer":true,"officer_title":"EVP, Head of R&D"}}],"security":"Common Stock","published_at":"2023-03-03T22:15:58.000Z","date":"2023-03-01","kind":"grant","acquired":true,"shares":141328,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"These restricted stock units vest in 12 equal quarterly installments on each Company Quarterly Vesting Date (as defined below), with the initial installment vesting on May 15, 2023, subject to the reporting person's continuous service. \"Company Quarterly Vesting Date\" means March 1, May 15, August 15 and November 15 of each year."}],"balance_after":295868,"source":{"system":"sec-edgar","filing":"0001140361-23-010100","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1553335/000114036123010100/form4.xml","form_type":"4"}},{"id":2109979,"issuer":{"id":6828,"kind":"organization","name":"Atara Biotherapeutics, Inc.","symbol":"ATRA"},"owners":[{"id":21169,"kind":"person","name":"Dupont Jakob","position":1,"cik":"0001553335","reported_name":"Dupont Jakob","relationship":{"officer":true,"officer_title":"EVP, Head of R&D"}}],"security":"Common Stock","published_at":"2022-11-19T01:13:49.000Z","date":"2022-11-16","kind":"sale","acquired":false,"shares":1124,"price":4.491,"value":5047.884,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Shares sold pursuant to a 10b5-1 arrangement to satisfy tax obligations in connection with the vesting of previously granted restricted stock units."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The sale price of the reporting person's shares represents the weighted average price of all shares sold by a broker on November 16, 2022 and November 17, 2022 on behalf of a group of employees of the Issuer to satisfy the payment of withholding tax liability of such employee."}],"balance_after":154540,"source":{"system":"sec-edgar","filing":"0001140361-22-042381","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1553335/000114036122042381/form4.xml","form_type":"4"}},{"id":2109978,"issuer":{"id":6828,"kind":"organization","name":"Atara Biotherapeutics, Inc.","symbol":"ATRA"},"owners":[{"id":21169,"kind":"person","name":"Dupont Jakob","position":1,"cik":"0001553335","reported_name":"Dupont Jakob","relationship":{"officer":true,"officer_title":"EVP, Head of R&D"}}],"security":"Common Stock","published_at":"2022-11-19T01:13:49.000Z","date":"2022-11-16","kind":"sale","acquired":false,"shares":3218,"price":4.49,"value":14448.82,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Shares sold pursuant to a 10b5-1 arrangement to satisfy tax obligations in connection with the vesting of previously granted restricted stock units."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The sale price of the reporting person's shares represents the weighted average price of all shares sold by a broker on November 16, 2022 and November 17, 2022 on behalf of a group of employees of the Issuer to satisfy the payment of withholding tax liability of such employee."}],"balance_after":155664,"source":{"system":"sec-edgar","filing":"0001140361-22-042381","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1553335/000114036122042381/form4.xml","form_type":"4"}},{"id":2147546,"issuer":{"id":110214,"kind":"organization","name":"Apexigen, Inc.","symbol":"APGN"},"owners":[{"id":21169,"kind":"person","name":"Dupont Jakob","position":1,"cik":"0001553335","reported_name":"Dupont Jakob","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2022-10-03T18:12:09.000Z","date":"2022-09-29","kind":"grant","acquired":true,"shares":100000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares subject to the option vest in three equal annual installments beginning on July 29, 2023."}],"balance_after":100000,"derivative":{"exercise_price":2.65,"expiration_date":"2032-09-29","underlying":"Common Stock","underlying_shares":100000},"source":{"system":"sec-edgar","filing":"0001209191-22-051935","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1814140/000120919122051935/doc4.xml","form_type":"4"}},{"id":2179139,"issuer":{"id":6828,"kind":"organization","name":"Atara Biotherapeutics, Inc.","symbol":"ATRA"},"owners":[{"id":21169,"kind":"person","name":"Dupont Jakob","position":1,"cik":"0001553335","reported_name":"Dupont Jakob","relationship":{"officer":true,"officer_title":"EVP, Head of R&D"}}],"security":"Common Stock","published_at":"2022-08-18T22:21:38.000Z","date":"2022-08-16","kind":"sale","acquired":false,"shares":4124,"price":5.034,"value":20760.216,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Shares sold pursuant to a 10b5-1 arrangement to satisfy tax obligations in connection with the vesting of previously granted restricted stock units."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The sale price of the reporting person's shares represents the weighted average price of all shares sold by a broker on August 16, 2022 on behalf of a group of employees of the Issuer to satisfy the payment of withholding tax liability of such employee."}],"balance_after":158882,"source":{"system":"sec-edgar","filing":"0001140361-22-030300","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1553335/000114036122030300/form4.xml","form_type":"4"}},{"id":2263205,"issuer":{"id":6828,"kind":"organization","name":"Atara Biotherapeutics, Inc.","symbol":"ATRA"},"owners":[{"id":21169,"kind":"person","name":"Dupont Jakob","position":1,"cik":"0001553335","reported_name":"Dupont Jakob","relationship":{"officer":true,"officer_title":"EVP, Head of R&D"}}],"security":"Common Stock","published_at":"2022-05-19T21:08:40.000Z","date":"2022-05-17","kind":"sale","acquired":false,"shares":3873,"price":5.318,"value":20596.614,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Shares sold pursuant to a 10b5-1 arrangement to satisfy tax obligations in connection with the vesting of previously granted restricted stock units."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The sale price of the reporting person's shares represents the weighted average price of all shares sold by a broker on May 17, 2022 and May 18, 2022 on behalf of a group of employees of the Issuer to satisfy the payment of withholding tax liability of such employee."}],"balance_after":163006,"source":{"system":"sec-edgar","filing":"0001140361-22-019981","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1553335/000114036122019981/form4.xml","form_type":"4"}},{"id":2352928,"issuer":{"id":6828,"kind":"organization","name":"Atara Biotherapeutics, Inc.","symbol":"ATRA"},"owners":[{"id":21169,"kind":"person","name":"Dupont Jakob","position":1,"cik":"0001553335","reported_name":"Dupont Jakob","relationship":{"officer":true,"officer_title":"EVP, Head of R&D"}}],"security":"Employee Stock Option (Right to Buy)","published_at":"2022-03-04T00:02:42.000Z","date":"2022-03-01","kind":"grant","acquired":true,"shares":147573,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"1/48th of the shares subject to the stock option vest and become exercisable each month with the initial installment vesting on April 1, 2022, subject to the reporting person's continuous service."}],"balance_after":147573,"derivative":{"exercise_price":10.21,"expiration_date":"2032-02-28","underlying":"Common Stock","underlying_shares":147573},"source":{"system":"sec-edgar","filing":"0001140361-22-007765","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1553335/000114036122007765/form4.xml","form_type":"4"}},{"id":2352927,"issuer":{"id":6828,"kind":"organization","name":"Atara Biotherapeutics, Inc.","symbol":"ATRA"},"owners":[{"id":21169,"kind":"person","name":"Dupont Jakob","position":1,"cik":"0001553335","reported_name":"Dupont Jakob","relationship":{"officer":true,"officer_title":"EVP, Head of R&D"}}],"security":"Common Stock","published_at":"2022-03-04T00:02:42.000Z","date":"2022-03-01","kind":"sale","acquired":false,"shares":2221,"price":9.856,"value":21890.176,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"Shares sold pursuant to a 10b5-1 arrangement to satisfy tax obligations in connection with the vesting of previously granted restricted stock units."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The sale price of the reporting person's shares represents the weighted average price of all shares sold by a broker on March 1, 2022 on behalf of a group of employees of the Issuer to satisfy the payment of withholding tax liability of such employee."}],"balance_after":166879,"source":{"system":"sec-edgar","filing":"0001140361-22-007765","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1553335/000114036122007765/form4.xml","form_type":"4"}},{"id":2352926,"issuer":{"id":6828,"kind":"organization","name":"Atara Biotherapeutics, Inc.","symbol":"ATRA"},"owners":[{"id":21169,"kind":"person","name":"Dupont Jakob","position":1,"cik":"0001553335","reported_name":"Dupont Jakob","relationship":{"officer":true,"officer_title":"EVP, Head of R&D"}}],"security":"Common Stock","published_at":"2022-03-04T00:02:42.000Z","date":"2022-03-01","kind":"grant","acquired":true,"shares":78506,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"These restricted stock units vest in 16 equal quarterly installments on each Company Quarterly Vesting Date (as defined below), with the initial installment vesting on May 15, 2022, subject to the reporting person's continuous service. Company Quarterly Vesting Date means March 1, May 15, August 15 and November 15 of each year."}],"balance_after":169100,"source":{"system":"sec-edgar","filing":"0001140361-22-007765","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1553335/000114036122007765/form4.xml","form_type":"4"}},{"id":2397184,"issuer":{"id":6828,"kind":"organization","name":"Atara Biotherapeutics, Inc.","symbol":"ATRA"},"owners":[{"id":21169,"kind":"person","name":"Dupont Jakob","position":1,"cik":"0001553335","reported_name":"Dupont Jakob","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Head of R&D"}}],"security":"Employee Stock Option (Right to Buy)","published_at":"2022-02-14T22:42:34.000Z","date":"2022-02-10","kind":"exercise","acquired":false,"shares":5000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Transaction pursuant to Rule 10b5-1 Plan adopted September 3, 2021."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"25% of the shares subject to the option vested on May 14, 2021 and the remaining shares vest in equal monthly installments over the following 36 months, subject to the reporting person's continuous service."}],"balance_after":257500,"derivative":{"exercise_price":9.58,"expiration_date":"2030-05-13","underlying":"Common Stock","underlying_shares":5000},"source":{"system":"sec-edgar","filing":"0001567619-22-004499","document":"doc1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1553335/000156761922004499/doc1.xml","form_type":"4"}},{"id":2397183,"issuer":{"id":6828,"kind":"organization","name":"Atara Biotherapeutics, Inc.","symbol":"ATRA"},"owners":[{"id":21169,"kind":"person","name":"Dupont Jakob","position":1,"cik":"0001553335","reported_name":"Dupont Jakob","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Head of R&D"}}],"security":"Common Stock","published_at":"2022-02-14T22:42:34.000Z","date":"2022-02-10","kind":"sale","acquired":false,"shares":5000,"price":16,"value":80000.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Transaction pursuant to Rule 10b5-1 Plan adopted September 3, 2021."}],"balance_after":90594,"source":{"system":"sec-edgar","filing":"0001567619-22-004499","document":"doc1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1553335/000156761922004499/doc1.xml","form_type":"4"}},{"id":2397182,"issuer":{"id":6828,"kind":"organization","name":"Atara Biotherapeutics, Inc.","symbol":"ATRA"},"owners":[{"id":21169,"kind":"person","name":"Dupont Jakob","position":1,"cik":"0001553335","reported_name":"Dupont Jakob","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Head of R&D"}}],"security":"Common Stock","published_at":"2022-02-14T22:42:34.000Z","date":"2022-02-10","kind":"exercise","acquired":true,"shares":5000,"price":9.58,"value":47900.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Transaction pursuant to Rule 10b5-1 Plan adopted September 3, 2021."}],"balance_after":95594,"source":{"system":"sec-edgar","filing":"0001567619-22-004499","document":"doc1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1553335/000156761922004499/doc1.xml","form_type":"4"}},{"id":2442867,"issuer":{"id":6828,"kind":"organization","name":"Atara Biotherapeutics, Inc.","symbol":"ATRA"},"owners":[{"id":21169,"kind":"person","name":"Dupont Jakob","position":1,"cik":"0001553335","reported_name":"Dupont Jakob","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Head of R&D"}}],"security":"Employee Stock Option (Right to Buy)","published_at":"2022-01-05T21:47:05.000Z","date":"2022-01-03","kind":"exercise","acquired":false,"shares":5000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Transaction pursuant to Rule 10b5-1 Plan adopted September 3, 2021."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"25% of the shares subject to the option vested on May 14, 2021 and the remaining shares vest in equal monthly installments over the following 36 months, subject to the reporting person's continuous service."}],"balance_after":262500,"derivative":{"exercise_price":9.58,"expiration_date":"2030-05-13","underlying":"Common Stock","underlying_shares":5000},"source":{"system":"sec-edgar","filing":"0001567619-22-000568","document":"doc1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1553335/000156761922000568/doc1.xml","form_type":"4"}},{"id":2442866,"issuer":{"id":6828,"kind":"organization","name":"Atara Biotherapeutics, Inc.","symbol":"ATRA"},"owners":[{"id":21169,"kind":"person","name":"Dupont Jakob","position":1,"cik":"0001553335","reported_name":"Dupont Jakob","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Head of R&D"}}],"security":"Common Stock","published_at":"2022-01-05T21:47:05.000Z","date":"2022-01-03","kind":"sale","acquired":false,"shares":5000,"price":16.01,"value":80050.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Transaction pursuant to Rule 10b5-1 Plan adopted September 3, 2021."}],"balance_after":90594,"source":{"system":"sec-edgar","filing":"0001567619-22-000568","document":"doc1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1553335/000156761922000568/doc1.xml","form_type":"4"}},{"id":2442865,"issuer":{"id":6828,"kind":"organization","name":"Atara Biotherapeutics, Inc.","symbol":"ATRA"},"owners":[{"id":21169,"kind":"person","name":"Dupont Jakob","position":1,"cik":"0001553335","reported_name":"Dupont Jakob","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Head of R&D"}}],"security":"Common Stock","published_at":"2022-01-05T21:47:05.000Z","date":"2022-01-03","kind":"exercise","acquired":true,"shares":5000,"price":9.58,"value":47900.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Transaction pursuant to Rule 10b5-1 Plan adopted September 3, 2021."}],"balance_after":95594,"source":{"system":"sec-edgar","filing":"0001567619-22-000568","document":"doc1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1553335/000156761922000568/doc1.xml","form_type":"4"}},{"id":2485137,"issuer":{"id":6828,"kind":"organization","name":"Atara Biotherapeutics, Inc.","symbol":"ATRA"},"owners":[{"id":21169,"kind":"person","name":"Dupont Jakob","position":1,"cik":"0001553335","reported_name":"Dupont Jakob","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Head of R&D"}}],"security":"Employee Stock Option (Right to Buy)","published_at":"2021-12-03T21:15:26.000Z","date":"2021-12-01","kind":"exercise","acquired":false,"shares":5000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Transaction pursuant to Rule 10b5-1 Plan adopted September 3, 2021."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"25% of the shares subject to the option vested on May 14, 2021 and the remaining shares vest in equal monthly installments over the following 36 months, subject to the reporting person's continuous service."}],"balance_after":267500,"derivative":{"exercise_price":9.58,"expiration_date":"2030-05-13","underlying":"Common Stock","underlying_shares":5000},"source":{"system":"sec-edgar","filing":"0001567619-21-021583","document":"doc1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1553335/000156761921021583/doc1.xml","form_type":"4"}},{"id":2485136,"issuer":{"id":6828,"kind":"organization","name":"Atara Biotherapeutics, Inc.","symbol":"ATRA"},"owners":[{"id":21169,"kind":"person","name":"Dupont Jakob","position":1,"cik":"0001553335","reported_name":"Dupont Jakob","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Head of R&D"}}],"security":"Common Stock","published_at":"2021-12-03T21:15:26.000Z","date":"2021-12-01","kind":"sale","acquired":false,"shares":5000,"price":17.9377,"value":89688.5,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Transaction pursuant to Rule 10b5-1 Plan adopted September 3, 2021."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price in Column 4 is a weighted average sale price. The prices actually received ranged from $17.78 to $18.135. The reporting person will provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, information regarding the number of shares sold at each price within the range."}],"balance_after":90594,"source":{"system":"sec-edgar","filing":"0001567619-21-021583","document":"doc1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1553335/000156761921021583/doc1.xml","form_type":"4"}},{"id":2485135,"issuer":{"id":6828,"kind":"organization","name":"Atara Biotherapeutics, Inc.","symbol":"ATRA"},"owners":[{"id":21169,"kind":"person","name":"Dupont Jakob","position":1,"cik":"0001553335","reported_name":"Dupont Jakob","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Head of R&D"}}],"security":"Common Stock","published_at":"2021-12-03T21:15:26.000Z","date":"2021-12-01","kind":"exercise","acquired":true,"shares":5000,"price":9.58,"value":47900.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Transaction pursuant to Rule 10b5-1 Plan adopted September 3, 2021."}],"balance_after":95594,"source":{"system":"sec-edgar","filing":"0001567619-21-021583","document":"doc1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1553335/000156761921021583/doc1.xml","form_type":"4"}},{"id":2504374,"issuer":{"id":6828,"kind":"organization","name":"Atara Biotherapeutics, Inc.","symbol":"ATRA"},"owners":[{"id":21169,"kind":"person","name":"Dupont Jakob","position":1,"cik":"0001553335","reported_name":"Dupont Jakob","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Head of R&D"}}],"security":"Common Stock","published_at":"2021-11-18T22:52:34.000Z","date":"2021-11-16","kind":"sale","acquired":false,"shares":2199,"price":17.1169,"value":37640.0631,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Shares sold pursuant to a 10b5-1 arrangement to satisfy tax obligations in connection with the vesting of previously granted Restricted Stock Units."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The sale price of the reporting person's shares represents the weighted average price of all shares sold by a broker on November 16, 2021 on behalf of a group of employees of the Issuer to satisfy the payment of withholding tax liability of such employees. The prices actually received ranged from $16.45 to $17.3823. The reporting person will provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, information regarding the number of shares sold on behalf of the group at each price within the range."}],"balance_after":90594,"source":{"system":"sec-edgar","filing":"0001567619-21-020777","document":"doc1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1553335/000156761921020777/doc1.xml","form_type":"4"}},{"id":2524251,"issuer":{"id":6828,"kind":"organization","name":"Atara Biotherapeutics, Inc.","symbol":"ATRA"},"owners":[{"id":21169,"kind":"person","name":"Dupont Jakob","position":1,"cik":"0001553335","reported_name":"Dupont Jakob","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Head of R&D"}}],"security":"Employee Stock Option (Right to Buy)","published_at":"2021-11-04T20:10:09.000Z","date":"2021-11-02","kind":"exercise","acquired":false,"shares":5000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Transaction pursuant to Rule 10b5-1 Plan adopted September 3, 2021."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"25% of the shares subject to the option vest on May 14, 2021 and the remaining shares vest in equal monthly installments over the following 36 months, subject to the reporting person's continuous service."}],"balance_after":272500,"derivative":{"exercise_price":9.58,"expiration_date":"2030-05-13","underlying":"Common Stock","underlying_shares":5000},"source":{"system":"sec-edgar","filing":"0001567619-21-019331","document":"doc1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1553335/000156761921019331/doc1.xml","form_type":"4"}},{"id":2524250,"issuer":{"id":6828,"kind":"organization","name":"Atara Biotherapeutics, Inc.","symbol":"ATRA"},"owners":[{"id":21169,"kind":"person","name":"Dupont Jakob","position":1,"cik":"0001553335","reported_name":"Dupont Jakob","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Head of R&D"}}],"security":"Common Stock","published_at":"2021-11-04T20:10:09.000Z","date":"2021-11-02","kind":"sale","acquired":false,"shares":5000,"price":16.41,"value":82050.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Transaction pursuant to Rule 10b5-1 Plan adopted September 3, 2021."}],"balance_after":92793,"source":{"system":"sec-edgar","filing":"0001567619-21-019331","document":"doc1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1553335/000156761921019331/doc1.xml","form_type":"4"}},{"id":2524249,"issuer":{"id":6828,"kind":"organization","name":"Atara Biotherapeutics, Inc.","symbol":"ATRA"},"owners":[{"id":21169,"kind":"person","name":"Dupont Jakob","position":1,"cik":"0001553335","reported_name":"Dupont Jakob","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Head of R&D"}}],"security":"Common Stock","published_at":"2021-11-04T20:10:09.000Z","date":"2021-11-02","kind":"exercise","acquired":true,"shares":5000,"price":9.58,"value":47900.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Transaction pursuant to Rule 10b5-1 Plan adopted September 3, 2021."}],"balance_after":97793,"source":{"system":"sec-edgar","filing":"0001567619-21-019331","document":"doc1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1553335/000156761921019331/doc1.xml","form_type":"4"}},{"id":2595861,"issuer":{"id":6828,"kind":"organization","name":"Atara Biotherapeutics, Inc.","symbol":"ATRA"},"owners":[{"id":21169,"kind":"person","name":"Dupont Jakob","position":1,"cik":"0001553335","reported_name":"Dupont Jakob","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Head of R&D"}}],"security":"Common Stock","published_at":"2021-08-19T23:32:27.000Z","date":"2021-08-17","kind":"sale","acquired":false,"shares":2152,"price":12.532,"value":26968.864,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Shares sold pursuant to a 10b5-1 arrangement to satisfy tax obligations in connection with the vesting of previously granted Restricted Stock Units."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The sale price of the reporting person's shares represents the weighted average price of all shares sold by a broker on August 17, 2021 and August 18, 2021 on behalf of a group of employees of the Issuer to satisfy the payment of withholding tax liability of such employees."}],"balance_after":92793,"source":{"system":"sec-edgar","filing":"0001567619-21-016145","document":"doc1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1553335/000156761921016145/doc1.xml","form_type":"4"}},{"id":2702541,"issuer":{"id":6828,"kind":"organization","name":"Atara Biotherapeutics, Inc.","symbol":"ATRA"},"owners":[{"id":21169,"kind":"person","name":"Dupont Jakob","position":1,"cik":"0001553335","reported_name":"Dupont Jakob","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Head of R&D"}}],"security":"Common Stock","published_at":"2021-05-20T20:32:56.000Z","date":"2021-05-18","kind":"sale","acquired":false,"shares":5184,"price":14.55,"value":75427.2,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Shares sold pursuant to a 10b5-1 arrangement to satisfy tax obligations in connection with the vesting of previously granted Restricted Stock Units."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The sale price of the reporting person's shares represents the weighted average price of all shares sold by a broker on May 18, 2021 and May 19, 2021 on behalf of a group of employees of the Issuer to satisfy the payment of withholding tax liability of such employees."}],"balance_after":94945,"source":{"system":"sec-edgar","filing":"0001209191-21-034428","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1553335/000120919121034428/doc4.xml","form_type":"4"}},{"id":2811566,"issuer":{"id":6828,"kind":"organization","name":"Atara Biotherapeutics, Inc.","symbol":"ATRA"},"owners":[{"id":21169,"kind":"person","name":"Dupont Jakob","position":1,"cik":"0001553335","reported_name":"Dupont Jakob","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Head of R&D"}}],"security":"Employee Stock Option (Right to Buy)","published_at":"2021-03-03T22:17:46.000Z","date":"2021-03-01","kind":"grant","acquired":true,"shares":81327,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"1/48th of the shares subject to the stock option vest and become exercisable each month with the initial installment vesting on April 1, 2021, subject to the reporting person's continuous service."}],"balance_after":81327,"derivative":{"exercise_price":17.105,"expiration_date":"2031-02-28","underlying":"Common Stock","underlying_shares":81327},"source":{"system":"sec-edgar","filing":"0001209191-21-017046","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1553335/000120919121017046/doc4.xml","form_type":"4"}},{"id":2811565,"issuer":{"id":6828,"kind":"organization","name":"Atara Biotherapeutics, Inc.","symbol":"ATRA"},"owners":[{"id":21169,"kind":"person","name":"Dupont Jakob","position":1,"cik":"0001553335","reported_name":"Dupont Jakob","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Head of R&D"}}],"security":"Common Stock","published_at":"2021-03-03T22:17:46.000Z","date":"2021-03-01","kind":"grant","acquired":true,"shares":53879,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"These restricted stock units vest in 16 equal quarterly installments on each Company Quarterly Vesting Date (as defined below), with the initial installment vesting on May 15, 2021, subject to the reporting person's continuous service.  Company Quarterly Vesting Date means March 1, May 15, August 15 and November 15 of each year."}],"balance_after":100129,"source":{"system":"sec-edgar","filing":"0001209191-21-017046","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1553335/000120919121017046/doc4.xml","form_type":"4"}},{"id":3142136,"issuer":{"id":6828,"kind":"organization","name":"Atara Biotherapeutics, Inc.","symbol":"ATRA"},"owners":[{"id":21169,"kind":"person","name":"Dupont Jakob","position":1,"cik":"0001553335","reported_name":"Dupont Jakob","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Head of R&D"}}],"security":"Employee Stock Option (Right to Buy)","published_at":"2020-05-19T23:17:54.000Z","date":"2020-05-14","kind":"grant","acquired":true,"shares":277500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"25% of the shares subject to the option vest on May 14, 2021 and the remaining shares vest in equal monthly installments over the following 36 months, subject to the reporting person's continuous service."}],"balance_after":277500,"derivative":{"exercise_price":9.58,"expiration_date":"2030-05-13","underlying":"Common Stock","underlying_shares":277500},"source":{"system":"sec-edgar","filing":"0001209191-20-030712","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1553335/000120919120030712/doc4.xml","form_type":"4"}},{"id":3142135,"issuer":{"id":6828,"kind":"organization","name":"Atara Biotherapeutics, Inc.","symbol":"ATRA"},"owners":[{"id":21169,"kind":"person","name":"Dupont Jakob","position":1,"cik":"0001553335","reported_name":"Dupont Jakob","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Head of R&D"}}],"security":"Common Stock","published_at":"2020-05-19T23:17:54.000Z","date":"2020-05-14","kind":"grant","acquired":true,"shares":46250,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"25% of the shares subject to these restricted stock units (\"RSUs\") vest on May 15, 2021 and 1/16th of the total number shares subject to the RSUs vest on each of the next 12 Quarterly Vesting Dates (as defined below), subject to the reporting person's continuous service. Company Quarterly Vesting Date means March 1, May 15, August 15 and November 15 of each year."}],"balance_after":46250,"source":{"system":"sec-edgar","filing":"0001209191-20-030712","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1553335/000120919120030712/doc4.xml","form_type":"4"}},{"id":3262110,"issuer":{"id":6928,"kind":"organization","name":"Gossamer Bio, Inc.","symbol":"GOSS"},"owners":[{"id":21169,"kind":"person","name":"Dupont Jakob","position":1,"cik":"0001553335","reported_name":"Dupont Jakob","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Stock Option (right to buy)","published_at":"2020-02-19T21:23:49.000Z","date":"2020-02-14","kind":"grant","acquired":true,"shares":71500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"25% of the total number of shares subject to the option will vest on February 14, 2021 and 1/48th of the total number of shares subject to the option vest on the last day of each one-month period thereafter, subject to the Reporting Person's continuous service to the Issuer on each such vesting date."}],"balance_after":71500,"derivative":{"exercise_price":14.55,"expiration_date":"2030-02-14","underlying":"Common Stock","underlying_shares":71500},"source":{"system":"sec-edgar","filing":"0001209191-20-010521","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1553335/000120919120010521/doc4.xml","form_type":"4"}},{"id":3262109,"issuer":{"id":6928,"kind":"organization","name":"Gossamer Bio, Inc.","symbol":"GOSS"},"owners":[{"id":21169,"kind":"person","name":"Dupont Jakob","position":1,"cik":"0001553335","reported_name":"Dupont Jakob","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Common Stock","published_at":"2020-02-19T21:23:49.000Z","date":"2020-02-14","kind":"grant","acquired":true,"shares":46500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents restricted stock unit award, which will vest in three equal annual installments in accordance with the terms of the award and subject to the Reporting Person's continuous service to the Issuer on each vesting date."}],"balance_after":46500,"source":{"system":"sec-edgar","filing":"0001209191-20-010521","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1553335/000120919120010521/doc4.xml","form_type":"4"}},{"id":3328692,"issuer":{"id":6928,"kind":"organization","name":"Gossamer Bio, Inc.","symbol":"GOSS"},"owners":[{"id":21169,"kind":"person","name":"Dupont Jakob","position":1,"cik":"0001553335","reported_name":"Dupont Jakob","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Non-qualified stock option (Right to Buy)","published_at":"2019-12-31T22:00:11.000Z","date":"2019-12-30","kind":"exercise","acquired":false,"shares":40000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option was granted on December 14, 2018. 25% of the total number of shares subject to the option vested on December 14, 2019 and 1/48th of the total number of shares subject to the option vest on the last day of each one-month period thereafter, subject to the Reporting Person's continuous service to the Corporation on each such vesting date."}],"balance_after":439317,"derivative":{"exercise_price":10.71,"expiration_date":"2028-12-13","underlying":"Common Stock","underlying_shares":40000},"source":{"system":"sec-edgar","filing":"0001209191-19-062303","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1553335/000120919119062303/doc4.xml","form_type":"4"}},{"id":3328691,"issuer":{"id":6928,"kind":"organization","name":"Gossamer Bio, Inc.","symbol":"GOSS"},"owners":[{"id":21169,"kind":"person","name":"Dupont Jakob","position":1,"cik":"0001553335","reported_name":"Dupont Jakob","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Non-qualified stock option (Right to Buy)","published_at":"2019-12-31T22:00:11.000Z","date":"2019-12-27","kind":"exercise","acquired":false,"shares":1994,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option was granted on December 14, 2018. 25% of the total number of shares subject to the option vested on December 14, 2019 and 1/48th of the total number of shares subject to the option vest on the last day of each one-month period thereafter, subject to the Reporting Person's continuous service to the Corporation on each such vesting date."}],"balance_after":479317,"derivative":{"exercise_price":10.71,"expiration_date":"2028-12-13","underlying":"Common Stock","underlying_shares":1994},"source":{"system":"sec-edgar","filing":"0001209191-19-062303","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1553335/000120919119062303/doc4.xml","form_type":"4"}},{"id":3328690,"issuer":{"id":6928,"kind":"organization","name":"Gossamer Bio, Inc.","symbol":"GOSS"},"owners":[{"id":21169,"kind":"person","name":"Dupont Jakob","position":1,"cik":"0001553335","reported_name":"Dupont Jakob","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Common Stock","published_at":"2019-12-31T22:00:11.000Z","date":"2019-12-30","kind":"sale","acquired":false,"shares":40000,"price":15.0001,"value":600004.0,"ownership":{"direct":true},"balance_after":0,"source":{"system":"sec-edgar","filing":"0001209191-19-062303","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1553335/000120919119062303/doc4.xml","form_type":"4"}},{"id":3328689,"issuer":{"id":6928,"kind":"organization","name":"Gossamer Bio, Inc.","symbol":"GOSS"},"owners":[{"id":21169,"kind":"person","name":"Dupont Jakob","position":1,"cik":"0001553335","reported_name":"Dupont Jakob","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Common Stock","published_at":"2019-12-31T22:00:11.000Z","date":"2019-12-30","kind":"exercise","acquired":true,"shares":40000,"price":10.71,"value":428400.0,"ownership":{"direct":true},"balance_after":40000,"source":{"system":"sec-edgar","filing":"0001209191-19-062303","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1553335/000120919119062303/doc4.xml","form_type":"4"}},{"id":3328688,"issuer":{"id":6928,"kind":"organization","name":"Gossamer Bio, Inc.","symbol":"GOSS"},"owners":[{"id":21169,"kind":"person","name":"Dupont Jakob","position":1,"cik":"0001553335","reported_name":"Dupont Jakob","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Common Stock","published_at":"2019-12-31T22:00:11.000Z","date":"2019-12-27","kind":"sale","acquired":false,"shares":1994,"price":15.8145,"value":31534.113,"ownership":{"direct":true},"balance_after":0,"source":{"system":"sec-edgar","filing":"0001209191-19-062303","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1553335/000120919119062303/doc4.xml","form_type":"4"}},{"id":3328687,"issuer":{"id":6928,"kind":"organization","name":"Gossamer Bio, Inc.","symbol":"GOSS"},"owners":[{"id":21169,"kind":"person","name":"Dupont Jakob","position":1,"cik":"0001553335","reported_name":"Dupont Jakob","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Common Stock","published_at":"2019-12-31T22:00:11.000Z","date":"2019-12-27","kind":"exercise","acquired":true,"shares":1994,"price":10.71,"value":21355.74,"ownership":{"direct":true},"balance_after":1994,"source":{"system":"sec-edgar","filing":"0001209191-19-062303","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1553335/000120919119062303/doc4.xml","form_type":"4"}},{"id":3578101,"issuer":{"id":6928,"kind":"organization","name":"Gossamer Bio, Inc.","symbol":"GOSS"},"owners":[{"id":21169,"kind":"person","name":"Dupont Jakob","position":1,"cik":"0001553335","reported_name":"Dupont Jakob","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Stock Option (right to buy)","published_at":"2019-03-26T22:57:26.000Z","date":"2019-03-25","kind":"grant","acquired":true,"shares":65000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"25% of the total number of shares subject to the option will vest on March 25, 2020 and 1/48th of the total number of shares subject to the option vest on the last day of each one-month period thereafter, subject to the Reporting Person's continuous service to the Corporation on each such vesting date."}],"balance_after":65000,"derivative":{"exercise_price":22.1,"expiration_date":"2029-03-25","underlying":"Common Stock","underlying_shares":65000},"source":{"system":"sec-edgar","filing":"0001209191-19-021370","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1553335/000120919119021370/doc4.xml","form_type":"4"}},{"id":4581438,"issuer":{"id":158190,"kind":"organization","name":"OncoMed Pharmaceuticals Inc","symbol":"OMED"},"owners":[{"id":21169,"kind":"person","name":"Dupont Jakob","position":1,"cik":"0001553335","reported_name":"Dupont Jakob","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP & Chief Medical Officer"}}],"security":"Common Stock","published_at":"2016-10-11T21:42:22.000Z","date":"2016-10-09","kind":"grant","acquired":true,"shares":12500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Restricted stock units (\"RSUs\"). The reporting person is entitled to receive one (1) share of common stock of the issuer for each one (1) RSU upon the vesting thereof."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Includes 27,500 restricted stock units and 1,298 shares acquired under the Issuer's Employee Stock Purchase Plan on February 29, 2016."}],"balance_after":34440,"source":{"system":"sec-edgar","filing":"0001140361-16-082539","document":"doc1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1302573/000114036116082539/doc1.xml","form_type":"4"}}]}